{"id":88331,"date":"2025-11-24T09:40:08","date_gmt":"2025-11-24T09:40:08","guid":{"rendered":"https:\/\/www.europesays.com\/se\/88331\/"},"modified":"2025-11-24T09:40:08","modified_gmt":"2025-11-24T09:40:08","slug":"nbl-faller-natreklam-for-allergimedicin","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/88331\/","title":{"rendered":"NBL f\u00e4ller n\u00e4treklam f\u00f6r allergimedicin"},"content":{"rendered":"<p>L\u00e4kemedelsf\u00f6retaget Kenvue marknadsf\u00f6r det receptfria antihistaminl\u00e4kemedlet Livostin (levokabastin) mot allergiska besv\u00e4r. L\u00e4kemedelsverket har reagerat mot f\u00f6retagets annonsering f\u00f6r Livostin p\u00e5 \u00a0Google, Facebook, Instagram och p\u00e5 webbplatsen nyheter24.se. Myndigheten anser att marknadsf\u00f6ringen strider mot L\u00e4kemedelsbranschens etiska regelverk, LER, och har d\u00e4rf\u00f6r anm\u00e4lt den till N\u00e4mnden f\u00f6r bed\u00f6mning av l\u00e4kemedelsinformation, NBL.<\/p>\n<p>Anm\u00e4lde annonser f\u00f6r Livostin<\/p>\n<p>Googleannonserna best\u00e5r av korta texter som beskriver Livostins anv\u00e4ndningsomr\u00e5de och g\u00f6r olika effektp\u00e5st\u00e5enden som \u201dN\u00e4sspray mot allergi\u201d, \u201dpollenmedicin\u201d och \u201dsnabb lindring\u201d. Men, framh\u00e5ller L\u00e4kemedelsverket i sin anm\u00e4lan, annonserna saknar information om l\u00e4kemedlets aktiva substans, vilket kr\u00e4vs enligt det etiska regelverket.<\/p>\n<p><strong>L\u00e4kemedelsverket anser \u00e4ven<\/strong> att annonserna saknar annan information om hur man anv\u00e4nder l\u00e4kemedlet p\u00e5 ett s\u00e4kert s\u00e4tt.<\/p>\n<p>F\u00f6retaget framh\u00e5ller i sitt svarom\u00e5l att den efterfr\u00e5gade informationen \u201dett klick bort\u201d p\u00e5 webbplatsen livostin.se som annonserna l\u00e4nkade till. Kenvue anser att marknadsf\u00f6ringen b\u00f6r ses som en helhet d\u00e4r webbplatsen ing\u00e5r och h\u00e4nvisar till tidigare NBL-beslut i fall som d\u00e5 g\u00e4llt bannerannonsering.<\/p>\n<p><strong>Men NBL g\u00e5r<\/strong> p\u00e5 L\u00e4kemedelsverkets linje. N\u00e4mnden tar fasta p\u00e5 att annonserna saknar upplysningen p\u00e5 den aktiva substansen och f\u00e4ller d\u00e4rf\u00f6r f\u00f6retaget.<\/p>\n<p>Ska betala straffavgift<\/p>\n<p>\u00c4ven n\u00e4r det g\u00e4ller annonser f\u00f6r Livostin p\u00e5 Facebook och Instagram ger NBL L\u00e4kemedelsverket r\u00e4tt och f\u00e4ller marknadsf\u00f6ringen. H\u00e4r best\u00e5r regelbrottet av att texten med produktinformation \u00e4r f\u00f6r liten och otydlig och att det g\u00e5r f\u00f6r snabbt innan texten f\u00f6rsvinner.<\/p>\n<p><strong>Kenvue ska betala<\/strong> en straffavgift p\u00e5 sammanlagt 110 000 kronor.<\/p>\n","protected":false},"excerpt":{"rendered":"L\u00e4kemedelsf\u00f6retaget Kenvue marknadsf\u00f6r det receptfria antihistaminl\u00e4kemedlet Livostin (levokabastin) mot allergiska besv\u00e4r. L\u00e4kemedelsverket har reagerat mot f\u00f6retagets annonsering f\u00f6r&hellip;\n","protected":false},"author":2,"featured_media":88332,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69],"tags":[113,112,34,31,33,32,30],"class_list":{"0":"post-88331","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-halsa","8":"tag-halsa","9":"tag-health","10":"tag-se","11":"tag-svenska","12":"tag-sverige","13":"tag-sweden","14":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115604017828737783","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/88331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=88331"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/88331\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/88332"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=88331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=88331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=88331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}